Modern Treatment Concepts in Schizophrenia

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 3, 2003, Pages

  Gaebel, W ^a   Janssen, B ^a   Riesbeck, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID RECEPTOR ANTAGONIST; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR AGONIST; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR ANTAGONIST; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFERENCE PAPER; COPING BEHAVIOR; DISEASE COURSE; DISEASE EXACERBATION; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; FAMILY THERAPY; HEALTH SURVEY; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; MENTAL STRESS; META ANALYSIS; OUTPATIENT; PATHOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACOGENETICS; PHARMACOGENOMICS; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; RELAPSE; REMISSION; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL STATUS; TARDIVE DYSKINESIA; TASK PERFORMANCE; TREATMENT OUTCOME; VERBAL MEMORY; VISUOMOTOR COORDINATION; WORKING MEMORY;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; DECISION TREES; DISEASE PROGRESSION; HUMANS; RECURRENCE; SCHIZOPHRENIA; SOCIAL ENVIRONMENT;

EID: 0346373730     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154: 4 (suppl)
2. American Psychiatric Association. Quick reference to the American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2002. American Psychiatric Publishing, Arlington: 2002
3. Amminger GP, Edwards J, Brewer WJ, Harrigan S, McGorry PD. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 2002; 54: 223-230
4. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-2530
5. Bechdolf A, Wagner M, Kühn K-U, Streit M, Bottlender R, Wieneke A, Schultze-Lutter F, Maier W, Klosterkötter J, Ruhrmann S. Interventions in the initial prodromal states of psychosis in Germany: concept and first results. Br J Psychiatry, 2003 (submitted)
6. Bleuler M. Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken-und Familiengeschichten. Stuttgart/New York: Thieme, 1972
7. Breier A, Schreiber JL, Dyer J, Pickar D. Course of illness and predictors of outcome in chronic schizophrenia: Implications for pathophysiology. Br J Psychiatry 1992; 161 (suppl 18): 38-43
8. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
9. Emsley R. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999; 25 (4): 721-729
10. Frommann N, Streit M, Wölwer W. Remediation of facial affect recognition impairments in patients with schizophrenia: a new training program. Psychiatry Res 2003; 117: 281-284
11. Gaebel W. Leitlinien störungspezifischer Diagnostik und Therapie -Schizophrenie. In: Gaebel W, Müller-Spahn F (eds). Diagnostik und Therapie psychischer Störungen Stuttgart/Berlin: Kohlhammer, 2002
12. Gaebel W, Jänner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. Prodromal states in schizophrenia. Compr Psychiatry 2000; 41: 76-85
13. Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpeke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. First vs. multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002; 53: 145-159
14. Gaebel W, Riesbeck M. Differentielle Indikation zur pharmakologischen Langzeittherapie bei Patienten mit schizophrenen Störungen. In: Fleischhacker WW, Hummer M (eds). Schizophrene Störungen - State of the Art Innsbruck: VIP-Verlag Integrative Psychiatrie, 2003; (in press)
15. Geddes J. Prevention of relapse in schizophrenia. N Engl J Med 2002; 346: 56-58
16. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systemic overview and meta-regression analysis. BMJ 2000; 32: 1371-1376
17. Goodman A. Organic unity theory: the mind-body problem revisited. Am J Psychiatry 1991; 148: 553-563
18. Gould RA, Mueser KT, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophr Res 2001; 48: 335-342
19. Green MF, Marder RS, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002; 51: 972-978
20. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-1322
21. Herz MI, Lamberti SJ. Prodromal symptoms and relapse prevention in schizophrenia. Schizophr Bull 1995; 21 (4): 541-551
22. Janssen B, Pourhassan F, Menke R, Vauth R, Schneider F, Gaebel W. Quality improvement in outpatient care of schizophrenic patients: a multicenter study. Schizophr Res 2001; 49: 272
23. Kahn RS, Fleischhacker W, Keet R et al. The European First Episode Schizophrenia Trial (EUFEST). Comparison of outcome in first episode schizophrenia with different antipsychotic drug regimes. 2001; (unpublished manuscript)
24. Koch K, Habel U, Frommann N, Klein M, Shah NJ, Kellermann T, Brinkmeyer J, Streit M, Zilles K, Wölwer W, Schneider F. Emotion discrimination training modifies functional cerebral correlates in schizophrenia patients. Neuroimage 2003; 18 (suppl): (in press)
25. Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Meile I, Opjordsmoen S, Simonsen E, Vaglum P. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatrica Scandinavica 2001; 103: 323-334
26. Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996; 57 (suppl 11): 61-67
27. Lehman AF, Steinwachs DM and the Co-Investigators of the PORT-Project. At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10
28. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
29. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159 (2): 180-190
30. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589
31. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156: 1138-1148
32. Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, Siddle R, Drake R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Faragher B, Dunn G. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry 2002; 43 (suppl): 91-97
33. Lieberman J. Comparative effectiveness of antipsychotic medications in patients with schizophrenia (trial design summary). 2000
34. Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res 2001; 51: 55-61
35. Marder S. Antipsychotic drugs and relapse prevention. Schizophr Res 1999; 35: S87-92
36. Marder RS, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. Schizophr Bull 2002; 28: 5-16
37. May PRA, Tuma AH, Yale C, Potepan P, Dixon WJ. Schizophrenia - A follow-up study of results of treatment. II. Hospital stay over two to five years. Arch Gen Psychiatry 1976; 33: 481-486
38. McEvoy J, Scheifler P, Frances A. The expert consensus guideline series: Treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60 (suppl 11): 3-80
39. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001; 51: 17-29
40. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with sub-threshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928
41. Mrazek PJ & Haggarty RJ. Committee on prevention of mental disorders. Washington DC: National Academy Press, 1994
42. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance, 2002: 43 (www.nice.org.uk)
43. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 1984; 10: 300-312
44. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. J Nerv Ment Dis 2001; 189: 278-287
45. Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr Res 1999; 37: 191-196
46. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson G. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79-87
47. Sartorius N, Fleischhacker W, Gjerris A, Kern U, Knapp M, Leonard B, Lieberman J, López-Ibor J, Van Raay B, Twomey E. The usefulness and use of second-generation antipsychotic medications. Current Opinion in Psychiatry 2002; 15 (suppl): 1-51
48. Scatton B, Sanger DJ. Pharmacological and molecular targets in the search for novel antipsychotics. Behavioural Pharmacology 2000; 11: 243-256
49. Streit M, Wölwer W, Gaebel W. Facial-affect recognition and visual scanning behaviour in the course of schizophrenia. Schizophr Res 1997; 24: 311-317
50. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms. An urban-rural comparison. Arch Gen Psychiatry 2001; 58: 663-668
51. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135-145
52. Wagner M, Frommann I, Brinkmeyer J, Wölwer W, Schröter A, Matuschek E, Pukrop R. Neuropsychological deficits in presumably prodromal subjects. European Archives of Psychiatry and Clinical Neuroscience 2002; 252: 2-3
53. Warner R. The prevention of schizophrenia: what interventions are safe and effective? Schizophr Bull 2001; 27: 551-562
54. Wölwer W, Buchkremer G, Häfner H, Klosterkötter J, Maier W, Möller HJ, Gaebel W. German research network on schizophrenia - bridging the gap between research and care. European Archives of Psychiatry and Clinical Neuroscience 2003; (submitted)
55. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up of a high-risk group. Schizophr Res 2003; 60: 21-32
56. Zubin J, Spring B. Vulnerability: A new view of schizophrenia. Journal of Abnormal Psychology 1977; 86: 103-126